Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China

ABSTRACT:

SUBMITTER: Li M 

PROVIDER: S-EPMC12350607 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature